Edition:
United States

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

26.65USD
23 Feb 2018
Change (% chg)

$0.10 (+0.38%)
Prev Close
$26.55
Open
$26.10
Day's High
$27.94
Day's Low
$24.51
Volume
185,670
Avg. Vol
88,346
52-wk High
$37.00
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share
Tuesday, 13 Feb 2018 08:45am EST 

Feb 13 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.94 MILLION COMMON SHARES PRICED AT $34.00PER SHARE.  Full Article

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock
Monday, 12 Feb 2018 04:33pm EST 

Feb 12 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES - ‍ANTICIPATES USING OFFERING PROCEEDS FOR PURPOSES INCLUDING CLINICAL & MANUFACTURING ACTIVITIES FOR CB 2679D, MARZEPTACOG ALFA​.  Full Article

RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences
Monday, 5 Feb 2018 09:32am EST 

Feb 5 (Reuters) - Catalyst Biosciences Inc ::RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 .  Full Article

Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln
Monday, 22 Jan 2018 05:17pm EST 

Jan 22 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.  Full Article

Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences
Wednesday, 27 Dec 2017 01:36pm EST 

Dec 28 (Reuters) - Catalyst Biosciences Inc ::NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING.  Full Article

Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock
Wednesday, 20 Dec 2017 09:11am EST 

Dec 20 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.1 MILLION SHARES OF COMMON STOCK, OFFERED AT A PRICE OF $9.50 PER SHARE TO PUBLIC​.  Full Article

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock
Tuesday, 19 Dec 2017 04:51pm EST 

Dec 19 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ANTICIPATES USING PROCEEDS FROM OFFERING FOR CLINICAL TRIALS, RESEARCH AND DEVELOPMENT ACTIVITIES, CAPEX.  Full Article

Catalyst Biosciences Appoints Edward Williams To Its Board
Thursday, 14 Dec 2017 08:30am EST 

Dec 14 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS.CATALYST BIOSCIENCES INC - BARRY SELICK, WHO HAS BEEN CHAIRMAN SINCE 2006, WILL STEP DOWN FROM BOARD EFFECTIVE FEB. 15, 2018.CATALYST BIOSCIENCES INC - ‍CURRENT BOARD MEMBER AUGUSTINE LAWLOR WILL REPLACE SELICK AS CHAIRMAN​.  Full Article

Catalyst biosciences Q3 loss per share $1.34
Thursday, 2 Nov 2017 08:30am EDT 

Nov 2 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update.Q3 loss per share $1.34.Catalyst Biosciences Inc - ‍phase 1/2 trial of factor IX CB 2679D is advancing with interim results expected by year-end​.Catalyst Biosciences Inc - ‍phase 2 trial of factor Fviia Marzeptacog Alfa (activated) on track for initiation by year-end​.Catalyst Biosciences- ‍believes existing capital resources will be sufficient to meet its projected operating requirements for at least next 12 months​.  Full Article

Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration
Tuesday, 24 Oct 2017 08:00am EDT 

Oct 24 (Reuters) - Catalyst Biosciences Inc ::Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases.Catalyst Biosciences - ‍under terms of agreement, co, mosaic will collaborate to improve pharmacokinetic (pk) properties of co's anti-c3 proteases​.Catalyst Biosciences Inc - ‍will retain global commercial rights for all collaboration products​.Catalyst Biosciences Inc - ‍for all collaboration products, mosaic will receive product sublicense fees and/or milestone payments and royalties​.  Full Article